{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:13:10Z","timestamp":1778584390742,"version":"3.51.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>As the first FDA-approved autologous cellular immunotherapy, Sipuleucel-T requires a comprehensive safety evaluation, particularly regarding its neurological and cardiovascular adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study analyzed adverse event signals associated with Sipuleucel-T using the FDA Adverse Event Reporting System (FAERS) database from 2010 to 2024, employing reporting odds ratio (ROR) methodology and logistic regression analysis. Adverse drug reaction signals were considered significant when the number of reports exceeded 3 and the lower limit of ROR (95% CI) was greater than 1. The analysis focused on associations between the target drug and both preferred terms (PT) and system organ classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Analysis of the FAERS database (\n                      <jats:italic toggle=\"yes\">n =<\/jats:italic>\n                      \u00a047\u00a0894\u00a0299) revealed Sipuleucel-T (\n                      <jats:italic toggle=\"yes\">n =<\/jats:italic>\n                      \u00a012 948) has no significant overall association with neurological system disorders [ROR\u00a0=\u00a00.98 (0.92\u20131.04)], but showed significant risks for specific events: cerebrovascular accident (ROR\u00a0=\u00a02.09), transient ischemic attack (ROR\u00a0=\u00a05.03), Guillain\u2013Barr\u00e9 syndrome (ROR\u00a0=\u00a03.22), and cardiovascular events including atrial fibrillation (ROR\u00a0=\u00a03.38), acute myocardial infarction (ROR\u00a0=\u00a05.08), and deep vein thrombosis (ROR\u00a0=\u00a05.18). Regression analysis demonstrated increased cerebrovascular risk in patients aged 70\u201380\u00a0years (OR\u00a0=\u00a03.55), while higher body weight (&gt;90 kg) served as a protective factor (OR\u00a0=\u00a00.30). Cerebrovascular events (CVE) exhibited a bimodal distribution, with 44.3% occurring after 6\u00a0months, suggesting potential long-term immunomodulatory effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The neurological toxicity of Sipuleucel-T is relatively modest. Age (70\u201380\u00a0years) and body weight were identified as independent predictors of CVEs during treatment, with higher body weight showing a protective effect. This study identifies high-risk population characteristics for Sipuleucel-T-associated CVEs, providing important data to support clinical safety measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003759","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:02:22Z","timestamp":1762768942000},"page":"2411-2427","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Vascular and neurological toxicity profile of Sipuleucel-T: a large-scale real-world pharmacovigilance study"],"prefix":"10.1097","volume":"112","author":[{"given":"Dandan","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongbing","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Hang","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sentao","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bufu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Shanghai, China"},{"name":"National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5176-7469","authenticated-orcid":false,"given":"Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"R1-20260512","doi-asserted-by":"crossref","first-page":"411\u201322","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20260512","doi-asserted-by":"crossref","first-page":"1067\u201396","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260512","first-page":"3360\u201368","article-title":"Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database","volume":"8","author":"Moey","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R4-20260512","doi-asserted-by":"crossref","first-page":"4172\u201380","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of Sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"key":"R5-20260512","doi-asserted-by":"crossref","first-page":"2935\u201337","DOI":"10.1002\/cncr.32785","article-title":"Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data","volume":"126","author":"Higano","year":"2020","journal-title":"Cancer"},{"key":"R6-20260512","doi-asserted-by":"crossref","first-page":"2934\u201335","DOI":"10.1002\/cncr.32786","article-title":"Potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data","volume":"126","author":"Dores","year":"2020","journal-title":"Cancer"},{"key":"R7-20260512","first-page":"100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"PJS"},{"key":"R8-20260512","first-page":"e14596","article-title":"Recurrent bilateral strokes in a patient treated with Sipuleucel-T for prostate cancer","volume":"13","author":"Gill","year":"2021","journal-title":"Cureus"},{"key":"R9-20260512","doi-asserted-by":"crossref","first-page":"110\u201316","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R10-20260512","doi-asserted-by":"crossref","first-page":"380\u201384","DOI":"10.1038\/pcan.2016.26","article-title":"Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?","volume":"19","author":"Howard","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R11-20260512","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12894-020-00713-3","article-title":"Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer","volume":"20","author":"Miyoshi","year":"2020","journal-title":"BMC Urol"},{"key":"R12-20260512","doi-asserted-by":"crossref","first-page":"761\u201367","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. food and drug administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"R13-20260512","doi-asserted-by":"crossref","first-page":"562\u201373","DOI":"10.1093\/jnci\/djaa021","article-title":"Putting the pieces together: completing the mechanism of action jigsaw for Sipuleucel-T","volume":"112","author":"Madan","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"R14-20260512","doi-asserted-by":"crossref","first-page":"2169\u201374","DOI":"10.1007\/s00415-021-10404-0","article-title":"Guillain-Barr\u00e9 syndrome in patients treated with immune checkpoint inhibitors","volume":"268","author":"Fan","year":"2021","journal-title":"J Neurol"},{"key":"R15-20260512","doi-asserted-by":"crossref","first-page":"71.e1\u201371.e14","DOI":"10.1016\/j.jtct.2024.12.002","article-title":"Neurotoxicity and rare adverse events in BCMA-Directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"R16-20260512","doi-asserted-by":"crossref","first-page":"534\u201339","DOI":"10.4161\/hv.19795","article-title":"Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer","volume":"8","author":"Gardner","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R17-20260512","doi-asserted-by":"crossref","first-page":"1220\u201329","DOI":"10.1056\/NEJMoa1500964","article-title":"Intravascular complications of central venous catheterization by insertion site","volume":"373","author":"Parienti","year":"2015","journal-title":"N Engl J Med"},{"key":"R18-20260512","doi-asserted-by":"crossref","first-page":"386\u201396","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"R19-20260512","doi-asserted-by":"crossref","first-page":"3448\u201356","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"R20-20260512","doi-asserted-by":"crossref","first-page":"1529\u201341","DOI":"10.1586\/14760584.2015.1099437","article-title":"Prostate cancer immunotherapy with Sipuleucel-T: current standards and future directions","volume":"14","author":"Wei","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"R21-20260512","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00005344-199500252-00003","article-title":"Cytokines regulate vascular functions related to stability of the atherosclerotic plaque","volume":"25","author":"Libby","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"R22-20260512","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrurol.2015.33","article-title":"Immunotherapy: Sipuleucel-T induces humoral antigen spread in patients with mCRPC","volume":"12","author":"Sidaway","year":"2015","journal-title":"Nat Rev Urol"},{"key":"R23-20260512","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"R24-20260512","doi-asserted-by":"crossref","first-page":"3619\u201330","DOI":"10.1158\/1078-0432.CCR-14-2334","article-title":"Humoral immune response against nontargeted tumor antigens after treatment with Sipuleucel-T and its association with improved clinical outcome","volume":"21","author":"GuhaThakurta","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R25-20260512","doi-asserted-by":"crossref","first-page":"1203896","DOI":"10.3389\/fendo.2023.1203896","article-title":"Non-linear dose-response relationship between body mass index and stroke risk in middle-aged and elderly Chinese men: a nationwide Longitudinal Cohort Study from CHARLS","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R26-20260512","doi-asserted-by":"crossref","first-page":"e2400426","DOI":"10.1002\/advs.202400426","article-title":"Adaptive metabolic responses facilitate blood-brain barrier repair in ischemic stroke via BHB-mediated epigenetic modification of ZO-1 expression","volume":"11","author":"Li","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"R27-20260512","doi-asserted-by":"crossref","first-page":"600\u201308","DOI":"10.1038\/s41391-019-0150-5","article-title":"Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy","volume":"22","author":"Deka","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R28-20260512","doi-asserted-by":"crossref","first-page":"472\u201395","DOI":"10.1161\/CIRCRESAHA.116.308398","article-title":"Stroke risk factors, genetics, and prevention","volume":"120","author":"Boehme","year":"2017","journal-title":"Circ Res"},{"key":"R29-20260512","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R30-20260512","doi-asserted-by":"crossref","first-page":"770025","DOI":"10.3389\/fcvm.2022.770025","article-title":"Incident stroke and its influencing factors in patients with type 2 diabetes mellitus and\/or hypertension: a prospective cohort study","volume":"9","author":"Chang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R31-20260512","doi-asserted-by":"crossref","first-page":"515\u201381","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol Rev"},{"key":"R32-20260512","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.3390\/ijms26083532","article-title":"Breaking the barrier: the role of proinflammatory cytokines in BBB dysfunction","volume":"26","author":"Gryka-Marton","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R33-20260512","first-page":"712\u201368","article-title":"Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology","volume":"74","author":"de Almeida Lgn","year":"2022","journal-title":"Pharmacol Rev"},{"key":"R34-20260512","doi-asserted-by":"crossref","first-page":"1132\u201348","DOI":"10.2174\/1568026611208011132","article-title":"Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases","volume":"12","author":"Siasos","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"R35-20260512","doi-asserted-by":"crossref","first-page":"100261","DOI":"10.1016\/j.esmoop.2021.100261","article-title":"Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients","volume":"6","author":"Kulkarni","year":"2021","journal-title":"ESMO Open"},{"key":"R36-20260512","doi-asserted-by":"crossref","first-page":"137\u201347","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"R37-20260512","doi-asserted-by":"crossref","first-page":"483\u201388","DOI":"10.1007\/s002280050498","article-title":"Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system","volume":"54","author":"Alvarez-Requejo","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R38-20260512","doi-asserted-by":"crossref","first-page":"e006628","DOI":"10.1136\/jitc-2022-006628","article-title":"Vaccinating against cancer: getting to prime time","volume":"11","author":"Chang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R39-20260512","doi-asserted-by":"crossref","first-page":"e002254","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of Sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R40-20260512","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/biomedicines10061419","article-title":"Phase II trial of Sipuleucel-T and stereotactic ablative body radiation for patients with metastatic castrate-resistant prostate cancer","volume":"10","author":"Hannan","year":"2022","journal-title":"Biomedicines"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:29:01Z","timestamp":1778581741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003759","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}